Insider Selling: Disc Medicine (NASDAQ:IRON) COO Sells $24,759.00 in Stock

Disc Medicine, Inc. (NASDAQ:IRON) COO Jonathan Yen-Wen Yu sold 300 shares of the stock in a transaction on Monday, August 24th. The stock was sold at an average price of $82.53, for a total value of $24,759.00. Following the completion of the transaction, the chief operating officer directly owned 54,324 shares in the company, valued at $4,483,359.72. This trade represents a 0.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Jonathan Yen-Wen Yu also recently made the following trade(s):

• On Tuesday, August 25th, Jonathan Yen-Wen Yu sold 8,796 shares of Disc Medicine stock. The shares were sold at an average price of $83.12, for a total value of $731,123.52.
• On Wednesday, August 12th, Jonathan Yen-Wen Yu sold 804 shares of Disc Medicine stock. The shares were sold at an average price of $82.64, for a total value of $66,442.56.
• On Tuesday, July 7th, Jonathan Yen-Wen Yu sold 100 shares of Disc Medicine stock. The stock was sold at an average price of $82.50, for a total value of $8,250.00.
• On Friday, June 26th, Jonathan Yen-Wen Yu sold 300 shares of Disc Medicine stock. The stock was sold at an average price of $72.50, for a total value of $21,750.00.
• On Monday, June 22nd, Jonathan Yen-Wen Yu sold 9,700 shares of Disc Medicine stock. The stock was sold at an average price of $72.66, for a total value of $704,802.00.
• On Tuesday, June 16th, Jonathan Yen-Wen Yu sold 18,612 shares of Disc Medicine stock. The shares were sold at an average price of $69.19, for a total value of $1,287,764.28.

Disc Medicine Stock Performance

NASDAQ IRON opened at $80.03 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 24.14 and a quick ratio of 24.14. Disc Medicine, Inc. has a 1-year low of $40.00 and a 1-year high of $99.50. The firm has a market capitalization of $3.07 billion, a P/E ratio of -12.16 and a beta of 1.00. The business’s 50-day simple moving average is $76.98 and its 200-day simple moving average is $70.04.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.71) by $0.17. Equities analysts predict that Disc Medicine, Inc. will post -6.61 EPS for the current year.

Institutional Trading of Disc Medicine

Several large investors have recently bought and sold shares of the company. State of Wyoming acquired a new position in shares of Disc Medicine during the second quarter worth $25,000. ANTIPODES PARTNERS Ltd purchased a new position in shares of Disc Medicine in the fourth quarter valued at $33,000. Allworth Financial LP acquired a new stake in Disc Medicine during the 2nd quarter valued at $46,000. Nykredit A S acquired a new stake in Disc Medicine during the 2nd quarter valued at $103,000. Finally, Persistent Asset Partners Ltd purchased a new stake in Disc Medicine during the 4th quarter worth $141,000. Institutional investors and hedge funds own 83.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on IRON. Morgan Stanley reissued an “overweight” rating and issued a $90.00 price objective on shares of Disc Medicine in a research report on Monday, August 17th. Wall Street Zen lowered shares of Disc Medicine from a “hold” rating to a “sell” rating in a report on Saturday. HC Wainwright upped their price target on shares of Disc Medicine from $118.00 to $120.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Wedbush reiterated an “outperform” rating and issued a $88.00 price target on shares of Disc Medicine in a report on Wednesday, June 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Disc Medicine in a research report on Friday, July 17th. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $106.50.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.